Lonza
Lonza is a Swiss chemicals contract development and manufacturing company (CDMO) operating across small molecules, biologicals, cell and gene, capsules, and health ingredients. CDMOs enable the use of state-of-the-art technology and equipment, bring scale, expertise and excellence to pharmaceutical manufacturing. CDMOs enable customers to deliver new, innovative medicines that help treat a wide range of diseases and accelerate the process to achieve commercial scale production. This results in lower cost and more effective medicines.
Website besuchen- Unternehmenswert
- US$42.8 bn
- Region
- Switzerland
- Thema
- Health
- Unterthema
- Pharmaceutical therapies
Impact-Bewertung
Over half of drug development is now aided by CDMOs, meaning a wide applicability across the pharmaceutical industry and within healthcare, and Lonza is the largest CDMO in the market. The company is purely focused on the manufacturing part of the value-chain with the key drug development steps taking place elsewhere. Drugs account for a relatively small proportion (10-20%) of total healthcare spending.
Fundamentale Qualität
Lonza is a very high-quality company that is set to benefit from a growing trend towards outsourcing manufacturing. Its competitive position is also protected by the increasing complexity of biologics which increase the barriers to entry.
UN-Nachhaltigkeitsziele
Lonza’s services support SDG 3 by enabling the production of lower cost, more effective medicines.
Mehr erfahrenRisiko negativer Auswirkungen
- Animal testing of pharmaceuticals (not done by Lonza)
- Manufacturing produces medical waste including plastics and toxic chemicals
- Manufacturing requires a substantial amount of water
Verwandte Einblicke Verwandte Inhalte
Sustainable
The next constraint on AI is not just energy, it's also water
Von Ty Lee
10. März 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
Von WHEB Investment Team
17. Feb. 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
Von WHEB Investment Team
19. Jan. 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
Von Seb Beloe
19. Jan. 2026 | 5 min read